((R)-4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine | 912440-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ((R)-4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine
• 英文别名: [(7R)-3-bromo-2,5-dimethoxy-7-bicyclo[4.2.0]octa-1(6),2,4-trienyl]methanamine
• CAS: 912440-88-1
• 化学式: C₁₁H₁₄BrNO₂
• 分子量: 272.14
• InChiKey: MPBCKKVERDTCEL-LURJTMIESA-N

物化性质

• 沸点：
  359.3±42.0 °C(Predicted)
• 密度：
  1.434±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Biomarkers in inflammatory bowel disease
  申请人：University of Tromsø

  公开号：US10012654B2

  公开（公告）日：2018-07-03

  The present invention provides a method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNFα therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNFα, IL-17 and IFN-y in a Gl mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in IR and continuing treatment if said patient is not in IR.

  本发明提供了一种确定已接受抗 TNFα 治疗的炎症性肠病（IBD）患者是否处于免疫学缓解期（IR）的方法，所述方法包括确定所述患者 Gl 粘膜样本中选自 TNFα、IL-17 和 IFN-y 的细胞因子水平。还提供了使用所述测定方法进行预后和治疗的方法，特别是如果所述患者处于IR期，则停止治疗，如果所述患者未处于IR期，则继续治疗。
• Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
  申请人：Cyrano Therapeutics, Inc.

  公开号：US10598672B2

  公开（公告）日：2020-03-24

  Disclosed herein are methods for diagnosing a subject with loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia. Also disclosed herein are methods and compositions for treating a subject for loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia.

  本文公开了用于诊断味觉或嗅觉丧失和/或失真（如嗅觉减退、嗅觉障碍、无嗅觉、幻嗅觉、低嗅觉、失嗅觉、幻嗅觉和/或老嗅觉）的方法。本文还公开了用于治疗受试者味觉或嗅觉丧失和/或扭曲的方法和组合物，例如，味觉减退症、味觉失调症、无嗅症、幻觉症、味觉减退症、味觉失调症、幻觉症和/或老年性味觉失调症。
• BIOMARKERS IN INFLAMMATORY BOWEL DISEASE
  申请人：University of Tromsø

  公开号：EP2936162A1

  公开（公告）日：2015-10-28
• METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL
  申请人：Henkin, Robert I.

  公开号：EP3108245A1

  公开（公告）日：2016-12-28
• [EN] BIOMARKERS IN INFLAMMATORY BOWEL DISEASE<br/>[FR] BIOMARQUEUR DANS LES MALADIES INFLAMMATOIRES DE L'INTESTIN
  申请人：UNIV TROMSØ

  公开号：WO2014096873A1

  公开（公告）日：2014-06-26

  The present invention provides a method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNFα therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNFα, IL-17 and IFN-y in a Gl mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in I R and continuing treatment if said patient is not in IR.